gdc
Leukemia

Drugs for Leukemia

Here are the financial support services available to patients receiving treatment for Leukemia.

Acute Lymphoblastic Leukemia (ALL)

Arranon (nelarabine)

Drug company: Novartis
800-245-5356

Arranon is a nucleoside metabolic inhibitor used for the treatment of patients with T-cell acute lymphoblastic leukemia.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arranon:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Arranon for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Arranon for free for 1 year, or until a prescription drug coverage becomes available to them.

Besponsa (inotuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Besponsa is a CD22-directed antibody-drug conjugate used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Besponsa:

Pfizer Oncology Together Co-Pay Program for IV

Through this program, privately insured patients pay $0 copay for Besponsa until the annual benefit of $25,000 is reached. There are no income requirements for this program.

Pfizer Patient Assistance Program

This program provides Besponsa free, or at a savings, for eligible patients with no healthcare coverage, as well as for patients with government insurance (who have no available independent charitable foundation support).

Blincyto (blinatumomab)

Drug company: Amgen
888-427-7478

Blincyto is a bispecific CD19-directed CD3 T-cell engager used for the treatment of patients with Ph– relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Amgen offers 2 financial assistance programs for patients using Blincyto:

Amgen Assist 360

Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.

Amgen Safety Net Foundation

Qualifying, uninsured patients can receive Blincyto for free through Amgen’s nonprofit patient assistance program.

Clolar (clofarabine)

Drug company: Sanofi
888-847-4877

Clolar injection is a purine nucleoside metabolic inhibitor used for the treatment of young patients up to age 21 who are diagnosed with relapsed or refractory acute lymphoblastic leukemia.

The Sanofi Patient Connection offers 1 financial assistance program for patients using Clolar:

Sanofi Patient Assistance Connection

Uninsured patients or patients who do not have access to Clolar through their insurance can apply to this program to receive free medication. Eligible patients must have an annual household income that is 500% or less of the federal poverty level. Patients enrolled in Medicare Part D must not be eligible for Low Income Subsidy, not have coverage for a generic equivalent, and have out-of-pocket drug expenses of 5% of their household’s annual income, in addition to meeting the requirements for uninsured patients.

Erwinaze (asparaginase Erwinia chrysanthemi)

Drug company: Jazz Pharmaceuticals
888-837-4397

Erwinaze (asparaginase Erwinia chrysanthemi) is an asparagine-specific enzyme used for the treatment of patients with acute lymphoblastic leukemia.

Jazz Pharmaceuticals offers 1 financial assistance program for patients using Erwinaze:

JumpStart Patient Assistance Program

This program offers free Erwinaze for patients who meet the program’s requirements.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used, in combination with chemotherapy, for the treatment of adults with relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) and pediatric patients with Ph+ ALL.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Gleevec $10 Co-Pay Card

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum annual benefit of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Gleevec for free for 1 year, or until a prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia (CML), or for adults with Ph+ acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. Iclusig is also used for adults with chronic, accelerated, or blast phase CML with T315I mutation, with Ph+ ALL and T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Iclusig 1Point

Regardless of patients’ insurance status, this program identifies the financial assistance programs for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.

Iclusig Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription, up to a maximum annual benefit of $25,000.

Kymriah (tisagenlecleucel)

Drug company: Novartis
844-459-6742

Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of young patients (up to age 25) with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Novartis’ Patient Assistance NOW offers 1 financial assistance program for patients using Kymriah:

Kymriah Cares

This program offers patient support and financial assistance for eligible patients. For more information visit www.us.kymriah.com/acute-lymphoblastic-leukemia-children/interested-in/patient-support

Marqibo (vincristine sulfate liposome)

Drug company: Spectrum
888-537-8277

Marqibo is a vinca alkaloid used for the treatment of adults with Phacute lymphoblastic leukemia.

Spectrum Therapy Access Resources (STAR) offers 2 financial assistance programs for patients using Marqibo:

STAR Co-Pay Assistance

With this program, patients pay $0 out of pocket for the first prescription, and STAR will cover 100% of the coinsurance/cost-share for Marqibo. For subsequent prescriptions, patients are responsible for the first $25 of the coinsurance/cost-share and STAR will cover 100% of the remainder. Up to $10,000 per calendar year is provided to assist with patient copay/coinsurance costs, and patients are responsible for additional out-of-pocket costs.

STAR Patient Assistance Program

This patient assistance program provides Marqibo free of charge to enrolled patients who meet the income, insurance, and citizenship/residency eligibility criteria.

Oncaspar (pegaspargase)

Drug company: Shire
888-229-8379

Oncaspar is an asparagine-specific enzyme used for the first-line treatment of patients with acute lymphoblastic leukemia (ALL) and for the treatment of patients with hypersensitivity to asparaginase.

Questions about patient assistance programs, copay assistance, and connections to reimbursement specialists should be directed to Shire’s Resource Helpline, 888-229-8379.

Purixan Suspension (mercaptopurine)

Drug company: Rare Disease Therapeutics
888-470-0904

Purixan (mercaptopurine) is a nucleoside metabolic inhibitor used as part of a combination maintenance treatment of patients with acute lymphoblastic leukemia.

(Rare Disease Therapeutics currently has no financial assistance programs for Purixan.)

Sprycel (dasatinib)

Drug company: Bristol-Myers Squibb
855-777-9235

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ acute lymphoblastic leukemia.

Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:

Sprycel Assist One Card

This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel with a reduced copay, in some cases $0 monthly, up to a maximum annual benefit of $32,000. New cash-paying patients or new patients covered by a government-funded program are eligible for a free 30-day trial supply of the medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Sprycel, may be eligible for help paying for their prescription if they are being treated as an outpatient and have an annual income up to 300% of the federal poverty level.

Acute Myeloid Leukemia (AML)

Idamycin PFS (idarubicin hydrochloride)

Drug company: Pfizer
866-706-2400

Idamycin PFS is used, in combination with other approved antileukemic drugs, for the treatment of patients with acute myeloid leukemia.

Pfizer Oncology Together offers 1 financial assistance program for patients using Idamycin PFS:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Idamycin PFS, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Idhifa (enasidenib) Tablets

Drug company: Celgene
800-931-8691

Idhifa is an IDH2 inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia with an IDH2 mutation.

Celgene offers 2 financial assistance programs for patients using Idhifa:

Celgene Commercial Co-pay Program

This program can reduce prescription copay to $25 and provides up to $10,000 per calendar year to cover copay or coinsurance costs for patients with private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication who meet certain financial criteria may qualify for the program.

Leukine (sargramostim)

Drug company: Sanofi
888-847-4877

Leukine is a recombinant human granulocyte-macrophage colony-stimulating factor used for the treatment of patients with acute myeloid leukemia, after induction chemotherapy.

Sanofi Patient Connection offers 2 financial assistance programs for patients using Leukine:

Leukine Direct Reimbursement Support Line

Sanofi provides patients and payers access to reimbursement consultants through this support line by calling 888-479-5385. The consultants can ensure patient and physician access to Leukine, answer reimbursement and coverage questions, help with claims preparation and claims appeal strategies, and identify available payment sources for uninsured or underinsured patients.

Sanofi Patient Assistance Connection

Patients who are uninsured or whose insurance does not cover Leukine can apply for financial assistance through this program. Eligible patients must have an annual household income of no more than 500% of the current federal poverty level. Patients with Medicare Part D can apply if they are not eligible for Low-Income Subsidy and have out-of-pocket drug costs that equal 5% or more of their annual income.

Mylotarg (gemtuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Mylotarg is a CD33-directed antibody-drug conjugate used for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, and relapsed or refractory CD33-positive AML in patients age 2 years or older.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Mylotarg:

Pfizer Oncology Together Co-Pay Program for IV

Eligible patients with private insurance may pay as little as $0 in copay with a maximum benefit of $25,000 per year. There are no income requirements.

Pfizer Patient Assistance Program

Eligible patients who do not have insurance and are unable to afford Mylotarg may receive their medicine free or at a savings through this program.

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for the treatment of adults with acute myeloid leukemia and FLT3 mutation.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-Pay Card Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $10 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Rydapt for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Rydapt for free for 1 year, or until a prescription drug coverage becomes available to them.

Vyxeos (daunorubicin and cytarabine) Liposome for Injection

Drug company: Jazz Pharmaceuticals
855-589-9367

Vyxeos is a liposomal combination of daunorubicin (an anthracycline topoisomerase inhibitor) and cytarabine (a nucleoside metabolic inhibitor) used for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Jazz Pharmaceuticals offers 1 financial assistance program for patients using Vyxeos:

JumpStart Patient Assistance Program

This program offers patients in the inpatient or outpatient setting improved access to Vyxeos and provides reimbursement support, including a benefits investigation and access to financial assistance options for eligible patients.

Zarxio (filgrastim-sndz)

Drug company: Sandoz
844-726-3691

Zarxio is a leukocyte growth factor used to reduce the time to neutrophil recovery and the duration of fever in patients with acute myeloid leukemia, after induction or consolidation chemotherapy treatment.

Sandoz One Source offers 1 financial assistance program for patients using Zarxio:

Sandoz One Source Co-Pay Program

Through this program, privately insured patients will pay $0 copay for the first dose of Zarxio and $10 for subsequent doses, with a maximum benefit of $10,000 annually. There is no income eligibility requirement.

Chronic Lymphocytic Leukemia (CLL)

Arzerra (ofatumumab)

Drug company: Novartis
800-245-5356

Arzerra is a CD20-directed cytolytic monoclonal antibody used for the treatment of patients with chronic lymphocytic leukemia. In certain cases, Arzerra is used in combination with chlorambucil, or fludarabine and cyclophosphamide.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arzerra:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Arzerra for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Arzerra for free for 1 year, or until a prescription drug coverage becomes available to them.

Bendeka (bendamustine hydrochloride)

Drug company: Teva
888-587-3263

Bendeka is an alkylating drug used for the treatment of patients with chronic lymphocytic leukemia.

Teva offers 1 financial assistance program for patients using Bendeka:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free. The financial criteria specify that the patient’s annual income must not exceed $60,300 for 1 person, $81,200 for 2 people, $102,100 for 3 people, $123,000 for 4 people, or $143,900 for 5 people.

Gazyva (obinutuzumab)

Drug company: Genentech
866-422-2377

Gazyva is a CD20-directed cytolytic antibody used, in combination with chlorambucil, for the treatment of patients with untreated chronic lymphocytic leukemia.

Genentech offers 2 financial assistance programs for patients using Gazyva:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Gazyva free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Gazyva is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Imbruvica (ibrutinib)

Drug company: Pharmacyclics
877-877-3536

Imbruvica is a kinase inhibitor used for the treatment of adult patients with chronic lymphocytic leukemia (CLL), and for patients with CLL and 17p deletion.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

You&i Instant Savings Program

Patients with private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and coinsurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Rituxan (rituximab)

Drug company: Genentech
866-422-2377

Rituxan is a CD20-directed cytolytic antibody used, in combination with fludarabine and cyclophosphamide, for the treatment of patients with chronic lymphocytic leukemia.

Genentech offers 2 financial assistance programs for patients using Rituxan:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Rituxan free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Rituxan is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Drug company: Genentech
866-422-2377

Rituxan Hycela is a combination of rituximab (a CD20-directed cytolytic antibody) and hyaluronidase human (an endoglycosidase) that is used, in combination with fludarabine and cyclophosphamide, for the treatment of untreated adults with chronic lymphocytic leukemia (CLL) and of previously treated CLL.

Genentech offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech BioOncology Co-pay Card

Privately insured patients will pay only a $25 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was refilled within 120 days before enrollment in this program.

Genentech Access to Care Foundation

This foundation provides Rituxan Hycela free of charge to uninsured and underinsured patients whose annual household income is less than $100,000, and Rituxan Hycela is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Treanda (bendamustine)

Drug company: Teva
888-587-3263

Treanda is an alkylating drug used for the treatment of patients with chronic lymphocytic leukemia.

Teva offers 1 financial assistance program for patients using Treanda:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Treanda for free. The financial criteria specify that the patient’s annual income must not exceed $60,300 for 1 person, $81,200 for 2 people, $102,100 for 3 people, $123,000 for 4 people, or $143,900 for 5 people.

Venclexta (venetoclax)

Drug company: Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used for the treatment of patients with chronic lymphocytic leukemia with 17p deletion.

Genentech offers 2 financial assistance programs for patients using Venclexta:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for Venclexta for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Venclexta free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Venclexta is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Zydelig (idelalisib)

Drug company: Gilead
844-622-2377

Zydelig is a kinase inhibitor used, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia.

Zydelig AccessConnect offers 3 financial assistance programs for patients using Zydelig:

Zydelig AccessConnect Copay Coupon Card

Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.

Zydelig QuickStart Program

The Zydelig QuickStart Program gives eligible patients who have an insurance coverage delay of more than 5 business days quick access to a free, one-time, 30-day supply of Zydelig.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Chronic Myeloid Leukemia (CML)

Bosulif (bosutinib)

Drug company: Pfizer
877-744-5675

Bosulif is a kinase inhibitor used for the treatment of adult patients with Ph+ chronic myeloid leukemia in the chronic, accelerated, or blast phase.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Bosulif:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Bosulif is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Bosulif for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Bosulif for free.

Busulfex (busulfan)

Drug company: Otsuka
855-242-7787

Busulfex is an alkylating drug used, in combination with cyclophosphamide, as a conditioning regimen before allogeneic hematopoietic progenitor-cell transplantation for the treatment of patients with chronic myeloid leukemia.

(Currently, Otsuka does not offer any financial resources for patients using Busulfex.)

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia in chronic, blast crisis, or accelerated phase, or in chronic phase after the failure of interferon-alpha therapy.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Gleevec $10 Co-Pay Card

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Gleevec for free for 1 year, or until a prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), or for adults with Ph+ acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. Iclusig is also used for adults with chronic, accelerated, or blast phase CML with T315I mutation, or with Ph+ ALL and T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Iclusig 1Point

Regardless of patients’ insurance status, this program identifies the financial assistance programs for which patients may be eligible and supports patients throughout their treatment by offering services to assist with day-to-day treatment-related concerns.

Iclusig Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or coinsurance for Iclusig.This program covers monthly out-of-pocket expenses of more than $10 per prescription up to a maximum annual benefit of $25,000.

Sprycel (dasatinib)

Drug company: Bristol-Myers Squibb
855-777-9235

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia.

Bristol-Myers Squibb offers 2 financial assistance programs for patients using Sprycel:

Sprycel Assist One Card

This card offers benefits for cash-paying patients, privately insured patients, and patients with public or government insurance. Privately insured patients can receive Sprycel with a reduced copay, in some cases $0 a month, up to a maximum annual benefit of $32,000. New cash-paying patients or new patients covered by a government-funded program are eligible for a free 30-day trial supply of Sprycel.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Sprycel, may be eligible for help paying for their prescription if they are receiving treatment as an outpatient and have an annual income up to 300% of the federal poverty level.

Synribo (omacetaxine)

Drug company: Teva
888-587-3263

Synribo is used for the treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia.

Teva offers 1 financial assistance program for patients using Synribo:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Synribo for free. The financial criteria specify that the patient’s annual income must not exceed $60,300 for 1 person, $81,200 for 2 people, $102,100 for 3 people, $123,000 for 4 people, or $143,900 for 5 people.

Tasigna (nilotinib)

Drug company: Novartis
800-245-5356

Tasigna is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Tasigna:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Tasigna. The program pays the remaining balance until an annual maximum of $15,000 is met.

Tasigna 3 Months Free Trial Voucher

Eligible new patients can receive a free 3-month trial supply of Tasigna capsules.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Tasigna for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Tasigna for free for 1 year, or until a prescription drug coverage becomes available to them.

Mast-Cell Leukemia

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used for the treatment of adults with mast-cell leukemia.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-Pay Card Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $10 per month. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Rydapt for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Rydapt for free for 1 year, or until a prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Leukemia

Acute Lymphoblastic Leukemia (ALL)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services




    Drug name (generic name)
  • Erwinaze (asparaginase Erwinia chrysanthemi)
  • Drug company
  • Jazz Pharmaceuticals
  • Indication
  • ALL
  • Patient support services
  • JumpStart Patient Assistance Program
    888-837-4397



    Drug name (generic name)
  • Kymriah (tisagenlecleucel)
  • Drug company
  • Novartis
  • Indication
  • B-cell precursor ALL in patients up to age 25
  • Patient support services
  • Kymriah Cares
    844-459-6742


    Drug name (generic name)
  • Oncaspar (pegaspargase)
  • Drug company
  • Shire
  • Indication
  • ALL
  • Patient support services
  • Shire’s Resource Helpline
    888-229-8379

    Drug name (generic name)
  • Purixan Suspension (mercaptopurine)
  • Drug company
  • Rare Disease Therapeutics
  • Indication
  • ALL
  • Patient support services
  • (No specific program)
    888-470-0904


Acute Myeloid Leukemia (AML)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Idamycin PFS (idarubicin hydrochloride)
  • Drug company
  • Pfizer
  • Indication
  • AML
  • Patient support services
  • Pfizer Patient Assistance Program
    866-706-2400





    Drug name (generic name)
  • Vyxeos (daunorubicin and cytarabine) Liposome for Injection
  • Drug company
  • Jazz Pharmaceuticals
  • Indication
  • Therapy-related AML

    AML with myelodysplasia related changes
  • Patient support services
  • JumpStart Patient Assistance Program
    855-589-936


Chronic Lymphocytic Leukemia (CLL)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Arzerra (ofatumumab)
  • Drug company
  • Novartis
  • Indication
  • CLL, sometimes in combination with chlorambucil, or with fudarabine and cyclophosphamide
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254








Chronic Myeloid Leukemia (CML)
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Busulfex (busulfan)
  • Drug company
  • Otsuka
  • Indication
  • CML, in combination with cyclophosphamide
  • Patient support services
  • (No specific program)
    855-242-7787


    Drug name (generic name)
  • Iclusig (ponatinib)
  • Drug company
  • Takeda
  • Indication
  • Adults with chronic-, accelerated-, or blast-phase CML
    Adults with chronic-, accelerated-, or blast-phase CML with T315I mutation
  • Patient support services
  • Iclusig 1Point


    Iclusig Co-Pay Assistance Program




Mast-Cell Leukemia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here